




165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK'S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE

Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of *Cancers*.

Rashid Ahmed, President and CEO, says, “This latest paper that was published a few days ago paper has been selected by the editors of the journal as the cover of the forthcoming issue. The issue cover will be displayed on the issue page: <https://www.mdpi.com/2072-6694/11>, and promoted in the issue released notification which will be sent to the journal subscribers together with the table of contents. I would like to thank and acknowledge the team for their excellent contribution that resulted in recognition of this manuscript.”

The paper is available through : <https://www.mdpi.com/2072-6694/11/8/1069> and or at <https://www.ncbi.nlm.nih.gov/pubmed/31362354>



About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (<https://medlineplus.gov/cancers.html>).

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.